Autopsy report · NCT01890577

Study of South African Dialysis Patients

“Study was terminated due to slow enrolment with no reasonable expectation of attaining a meaningful sample size”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 28 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Sponsor

Amgen

Sponsor type

Industry

Conditions

Chronic Kidney Disease, Receiving Dialysis

Interventions

Aranesp

Participants

28

Sites

7

Countries

South Africa

Trials that died the same way

• OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)
  “Study stopped because slow enrolment.” (79% match in meaning)
• Placebo Controlled Trial of Bosentan in Scleroderma Patients
  “Study was terminated due to inadequate enrolment” (79% match in meaning)
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  “Study was terminated due to slow accrual.” (77% match in meaning)
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
  “Study terminated due to slow/insufficient accrual.” (76% match in meaning)
• Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
  “Study was terminated due to slow accrual rate.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.